InflaRx (IFRX) Net Cash Flow (2016 - 2026)
InflaRx (IFRX) posted Net Cash Flow of -$1.6 million for Q1 2026, down 113.82% sequentially from $11.3 million in Q4 2025, and down 104.82% YoY from $32.2 million in Q1 2025.
InflaRx (IFRX) Net Cash Flow (2016 - 2026) Analysis & Trends
InflaRx has reported Net Cash Flow for 11 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly Net Cash Flow fell 104.82% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.8 million (down 244.42% YoY) and the FY2025 annual result came in at $1.4 million, down 69.25% from the prior year.
- Net Cash Flow fell to -$1.6 million in Q1 2026 per IFRX's latest filing, from $11.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $32.2 million in Q1 2025 and troughed at -$36.9 million in Q2 2025.
- A 5-year average of -$745579.3 and a median of -$1.2 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Net Cash Flow surged 481.49% in 2022, then slumped 616.19% in 2023.
- Over 5 years, Net Cash Flow stood at -$1.2 million in 2022, then plunged by 616.19% to -$8.8 million in 2023, then declined by 12.95% to -$9.9 million in 2024, then jumped by 213.69% to $11.3 million in 2025, then sank by 113.82% to -$1.6 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$1.6 million, $11.3 million, and -$7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 225.59 Mn |
| 10 | InflaRx | 138.28 Mn | -45.97 Mn | 2.74 Bn | 150.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.56 Mn |
| Mar 31, 2026 | -1.56 Mn |
| Dec 31, 2025 | 11.25 Mn |
| Dec 31, 2025 | 11.25 Mn |
| Sep 30, 2025 | -7.62 Mn |
| Sep 30, 2025 | -7.62 Mn |
| Jun 30, 2025 | -36.86 Mn |
| Jun 30, 2025 | -36.86 Mn |
| Mar 31, 2025 | 32.24 Mn |
| Mar 31, 2025 | 32.24 Mn |
| Dec 31, 2024 | -9.90 Mn |
| Dec 31, 2024 | -9.90 Mn |
| Sep 30, 2024 | 8.47 Mn |
| Sep 30, 2024 | 8.47 Mn |
| Jun 30, 2024 | -6.73 Mn |
| Jun 30, 2024 | -6.73 Mn |
| Mar 31, 2024 | 13.03 Mn |
| Mar 31, 2024 | 13.03 Mn |
| Dec 31, 2023 | -8.76 Mn |
| Dec 31, 2023 | -8.76 Mn |